-
1 week ago | 
oncologynewscentral.com | Youssef Rddad |Manali Bhave |Robert A. Figlin |Stephanie Graff
This transcript has been lightly edited for clarity. Robert A. Figlin, MD, FACP: Hello, this is Bob Figlin, the Cancer Center Director at Cedars-Sinai Cancer and the Steven Spielberg Family Chair in Hematology-Oncology. And I’m absolutely delighted to have back Erika Hamilton, who is the director of breast cancer and gynecologic cancer research at Sarah Cannon in Nashville, and a past chair of the American Society of Clinical Oncology (ASCO) Scientific Breast Committee. Erika, welcome.
-
2 weeks ago | 
oncologynewscentral.com | Debra Patt |Robert A. Figlin
This transcript has been lightly edited for clarity. Robert A. Figlin, MD, FACP: Good afternoon. This is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. And I’m absolutely delighted today to be joined by Debra Patt, who is both a practicing oncologist and breast cancer specialist in Austin, Texas.
-
1 month ago | 
oncologynewscentral.com | Robin Zon |Robert A. Figlin
Oncologist burnout and career dissatisfaction are a “huge problem,” says Robin T. Zon, MD, president of the American Society of Clinical Oncology (ASCO). Dr. Zon sits down with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, to discuss revelations from a recent ASCO report.
-
2 months ago | 
oncologynewscentral.com | Nathan Cherny |Robert A. Figlin
When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in our training,” says Nathan I. Cherny, MD, director of the Cancer Pain and Palliative Medicine Unit at Shaare Zedek Medical Center in Jerusalem, Israel. Dr. Cherney and colleagues recently examined factors contributing to oncologists overtreating patients at the end of life. He discusses key findings and ways to address this continued problem with Robert A.
-
Apr 16, 2024 | 
obroncology.com | Jennifer A. Woyach |Robert A. Figlin
The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A.
-
Apr 3, 2024 | 
obroncology.com | Paul A Bunn |Robert A. Figlin
CORRECTION 4/12/24: This podcast and transcript were edited to correct the description of the MARIPOSA trial as testing amivantamab plus osimertinib when it compares amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer. Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced?
-
Mar 28, 2024 | 
obroncology.com | Edwin M. Posadas |Robert A. Figlin
The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center in Los Angeles. Data from the recent EMBARK trial have changed practice for the treatment of men with high-risk features. Dr. Posadas discusses these findings and related advances with Robert A.
-
Mar 25, 2024 | 
obroncology.com | Jeffrey Weber |Robert A. Figlin
The U.S. Food and Drug Administration’s recent accelerated approval for a tumor-infiltrating lymphocytes (TIL) therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work with the treatment in the late 1980s, discusses the breakthrough with Robert A.
-
Mar 8, 2024 | 
obroncology.com | Robert Dreicer |Robert A. Figlin
Recent advances in metastatic urothelial carcinoma care have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville.
-
Feb 14, 2024 | 
obroncology.com | Robert A. Figlin
Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles A. Dewey Professor at the University of Rochester in New York, highlights which recent developments regarding second- and third-line treatments are most essential. She and Robert A.
